TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 176 filers reported holding TRAVERE THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 1.28 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $871,765 | -41.3% | 97,513 | +0.8% | 0.00% | -33.3% |
| Q2 2023 | $1,485,955 | -31.1% | 96,742 | +0.8% | 0.00% | -25.0% |
| Q1 2023 | $2,158,162 | +92.9% | 95,961 | +80.4% | 0.00% | +100.0% |
| Q4 2022 | $1,118,900 | +46.8% | 53,205 | +71.7% | 0.00% | 0.0% |
| Q3 2022 | $762,000 | -27.7% | 30,996 | -28.9% | 0.00% | 0.0% |
| Q2 2022 | $1,054,000 | -14.9% | 43,576 | -9.5% | 0.00% | 0.0% |
| Q1 2022 | $1,238,000 | -40.7% | 48,144 | -28.4% | 0.00% | -33.3% |
| Q4 2021 | $2,087,000 | +0.3% | 67,281 | -21.6% | 0.00% | -25.0% |
| Q3 2021 | $2,080,000 | +41.9% | 85,856 | -14.7% | 0.00% | +100.0% |
| Q2 2021 | $1,466,000 | -62.9% | 100,643 | -36.5% | 0.00% | -71.4% |
| Q1 2021 | $3,956,000 | – | 158,475 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |